Transcript Highlights:

• Naturally occurring compound. Okay. What about HHC?
• Naturally occurring compound. Okay. What about HHC?
• I also know that even with pharmaceuticals, every person is different.
• Our bodies Know that even with pharmaceuticals, every person is different.
• And since then, I have suffered from the pharmaceutical industry.

Bills: SB 3, HB28, SB3

Keywords: flash flood, flood warning, outdoor warning siren, emergency alert, disaster preparedness, flood mitigation, Hill Country floods, Texas Water Development Board, municipalities, counties, local government mandate, public safety, grant program, backup power, weather siren, emergency management, flood-prone area, warning system, hemp regulation, consumable products

Transcript Highlights:

• This straightforward adjustment is essential for controlling escalating pharmaceutical costs and ensuring
• This straightforward adjustment is essential for controlling, escalating pharmaceutical costs and ensuring
• It's important to note that payers across the board typically, pharmaceutical expenditures.
• Most prescriptions are made out of chemical compounds, not DNA.
• So making sure that we had other options other than a chemical compound.

Summary: The committee heard several bills, but much of the meeting focused on House Bill 306, which would require disclosure when a consumer is interacting with a chatbot rather than a human. Sponsor Senator Townsend described it as a consumer protection measure and said the bill is meant to keep pace with rapidly changing AI technology. Committee members and witnesses raised concerns about the bill’s enforcement structure, especially private rights of action and penalties that could apply even without actual consumer harm. The Department of Justice said the bill would apply where the conduct has a Delaware nexus, and that the disclosure requirement is the key consumer protection. Industry witnesses and chambers of commerce opposed the bill as drafted, arguing it would create broad compliance burdens and expose businesses to excessive litigation risk without a harm requirement or clearer safe harbor language. Earlier in the meeting, the committee discussed House Bill 429, which would update Delaware’s step therapy exception process to include biosimilars and interchangeable biologics. Senator Poore and supporters from Highmark and the Department of Insurance said the bill would modernize insurance law, improve access to effective treatments, and reduce costs; they cited national savings from biosimilars and said the bill has agency support. Members asked about Delaware-specific savings, patient switching, and how the process would work, but no vote was taken during the discussion. The committee also heard House Bill 310, which would exclude large data centers from Blue Collar Jobs Act tax credits; the sponsor said the bill is intended to ensure large energy users contribute more to state and local revenues, while supporters and opponents debated competitiveness and community impacts. House Bill 406, on allowing insureds to choose their auto repair shop, and Senate Bill 347, a cleanup bill related to medical debt collection and personal property levies, were also presented without opposition in the hearing. House Bill 253, concerning who may receive letters testamentary or of administration, was described as a cleanup to align statute with existing practice. The committee approved the meeting minutes, but the transcript does not show final votes on the bills discussed.

Transcript Highlights:

• that is not prescribed in any way, shape, or form, but coming completely when the issue that the pharmaceutical
• the doctors, the physicians, as well as nurse practitioners, as well as PAs, were going by the pharmaceutical
• The pharmaceutical companies were wrong. Correct.
• The information is super important because so many of our doctors and nurses, etc., rely on the pharmaceutical

Bills: HB35, HB4490, HB4454, HB2188, HB3078, HB4743, HB2556, HB46, HB5342, HB4783, HB3785, HB5278, HB1639, HB2581, HB4224, HB4070, HB4099, HB4882, HB3794, HB46

Keywords: peer support, first responders, mental health, confidentiality, emergency services, disclosure, next of kin, public information, deceased persons, privacy rights, patient solicitation, marketing practices, healthcare regulation, task force, deceptive advertising, nurse aide, certification, Texas Board of Nursing, healthcare workforce, nursing standards

Transcript Highlights:

• be compounded.
• Are you making the compound and doing it?
• That's my concern, as I am a firsthand user of compounding.
• The rules already require that compounding pharmacies...
• It's a pharmaceutical.

Bills: HB46, HB35, HB4490, HB4454, HB2188, HB3078, HB4743, HB2556, HB46, HB5342, HB4783, HB3785, HB5278, HB1639, HB2581, HB4224, HB4070, HB4099, HB4882, HB3794

Keywords: local government spending cap, expenditure limit, political subdivision, property tax, ad valorem tax, budget cap, taxpayer protection, spending restraint, inflation adjustment, population growth, voter approval, supermajority vote, county budget, municipal budget, school district finance, junior college district, hospital district, special district, attorney general enforcement, local fiscal limits

Transcript Highlights:

• The pharmaceutical cocktails.
• I don't like pharmaceutical medicine.
• Naturally occurring compound. Okay, what about H-H-C?
• I also know that, even with pharmaceuticals, every person is different.
• It freed me from the pharmaceutical chains I thought I'd be bound to. forever.

Bills: HB 28, SB 3

Keywords: hemp regulation, consumable products, cannabinoids, state health, youth protection, licensing fees, criminal offenses, HB28, public testimony, committee decorum, bill substitute, legislative process

Summary: The meeting featured significant discussions regarding HB28, where the chair outlined the plans to bring forward a substitute for the bill. The chair emphasized the importance of maintaining order and decorum during the proceedings. Members engaged in deliberations, and a number of public witnesses were invited to testify, thereby enriching the discussion around the bill. This interaction provided valuable insights into public sentiment regarding the issues at hand.

Transcript Highlights:

• So ibogaine is the only compound that we know of that can actually be given to somebody when they're
• On December 14, 1995, the FDA approved Purdue Pharmaceuticals OxyContin for, quote, the management of
• So how do we guarantee through the FDA approval process and the pharmaceutical, would it be a. pharmaceutical
• So one thing we know about ibogaine too is it's a class of compounds that are called cycloplastogens.
• So you can think from a pharmaceutical.

Bills: SB128, SB640, SB672, SB904, SB1141, SB1263, SB1525, SB1528, SB2041, SB2306, SB2308, SB2357, SB2446, SB2695, SB2857, SB2891, SB2583

Keywords: hospital reporting, child abuse, neglect, administrative penalty, medical ethics, child protection, SB 640, Texas Family Code, Department of Family and Protective Services, DFPS, child welfare, foster care, managing conservatorship, suicide attempt, youth suicide, mental health, child protective services, state custody, annual report, reporting requirements

Transcript Highlights:

• I've been through the gamut: brain surgery, a stimulator implanted in my face, over 30 pharmaceuticals
• I took so many pharmaceuticals that literally made it so I couldn't even drive.
• I took so many pharmaceuticals that literally made it so I couldn't even drive because they had such
• , involved mitragynine or an associated compound without any other drugs present.
• would not address the broader range of kratom products and compounds implicated in other deaths.

Summary: The Kratom Working Group met to hear public testimony and expert presentations on whether North Dakota should prohibit or regulate kratom and 7-OH products. Early testimony split sharply between speakers who described natural kratom as a helpful, lower-risk alternative for chronic pain, opioid withdrawal, PTSD, and recovery, and speakers who urged prohibition because of dependence, overdose risk, and the growth of concentrated or synthetic 7-OH products sold in gas stations, smoke shops, and online. Several witnesses, including consumers and shop owners, argued that banning kratom would push people to more dangerous drugs or unregulated internet sources, while public health and medical witnesses said the marketplace is confusing and inadequately controlled. A number of witnesses, including representatives of the North Dakota Public Health Association, the state crime lab, and addiction-treatment and pediatric clinicians, emphasized risks from adulterated or concentrated products, lack of labeling and age restrictions, contamination concerns, and harms to adolescents, pregnant patients, and newborns. The crime lab described recent cases involving mitragynine, 7-OH, and pseudoindoxyl, and said products purchased in a smoke shop were inaccurately labeled. A Sanford pediatric hospitalist testified that kratom exposure in pregnancy can cause severe neonatal withdrawal and that adolescents are using the product. By contrast, American Kratom Association representatives and other advocates argued that natural leaf kratom should be distinguished from synthetic 7-OH, that deaths usually involve other substances, and that a regulatory framework with testing, labeling, age limits, and product registration would better protect consumers than a blanket ban. No formal bill was debated or voted on in this transcript. The working group heard testimony, asked questions, and took no final action before breaking for lunch and later resuming with additional presentations.

Transcript Highlights:

• </c><04:13:29.120><c> So,</c> pharmaceutical takeback program. So, pharmaceutical takeback program.
• ,</c> pharmaceuticals, there's heavy metals, pharmaceuticals, there's heavy metals, there's<05:26:20.320
• </c> products made with PAS compounds products made with PAS compounds breathing<05:42:28.878><c> air
• PFAS compounds are no longer going to be there, and no progress will be made until compounds are no longer
• </c> making and using these PAS compounds. making and using these PAS compounds.

Keywords: 928, house, all

Summary: The Environmental Policy Subcommittee took up HB 1621, which would require a baseline environmental impact study before development of certain manufacturing and storage facilities. Members said the concept had merit, but they could not resolve major drafting and implementation issues, including how to define covered facilities, what the study would require, and how enforcement would work at the municipal or county level. Several members expressed concern about unintended consequences and said the proposal was not ready; the subcommittee voted unanimously to recommend inexpedient to legislate (ITL), and the full committee later adopted that recommendation on a 16-0 roll call vote, placing the bill on consent. The committee then discussed HB 1053, involving electronically submitted pesticide use reports. Representative Comtois presented an amendment creating a department database and protecting confidential information, but said she still needed to check whether it was germane and to review administrative issues with the Department of Agriculture. After hearing from David Russo of the Division of Pesticide Control, the committee agreed to continue work on the amendment and took no action that day. The committee also reviewed HB 1186 on egg labeling and producer exemptions. Representative Comtois offered an amendment exempting small producers from most requirements except labeling, but Commissioner Sean Jasper asked for more time to review the impact and suggested the state might not need the existing egg law at all if federal USDA rules already cover the field. Members agreed to hold action until the following week. Finally, the committee began discussion of HB 1780 on penalties for violations involving seeds, plants, and nursery stock, focusing on labeling rules and germination-date requirements; testimony from industry and department representatives indicated they were working toward a compromise that would allow multiple relabelings, add production dates, and set a 36-month sale limit, but no final action was taken in the portion provided.

Transcript Highlights:

• We heard a little bit already about antimicrobial resistance, or AMR, which compounds the concerns of
• Swanson, is that you both talked about pharmaceuticals. I don't think that gets mentioned.
• multiplier that the pharmaceutical industry will have to catch up with.
• And I'm assuming you don't have to pump these cells full of pharmaceuticals. No, at all.
• And I'm assuming you don't have to pump these cells full of pharmaceuticals. No, not at all.

Summary: The Select Committee on Alternative Protein Innovation held its first informational hearing to examine the state of alternative protein research, industry growth, and policy needs in California. The chair opened by noting California’s $5 million public investment in UC research in 2022 and framed the hearing around three panels: the climate, environmental, and security potential of alternative proteins; industry scaling and commercialization; and university-led research and workforce development. Members emphasized that the committee will continue with site visits and additional hearings across the state. The first panel focused on the case for alternative proteins as a climate, land, water, biodiversity, and food-security solution. Shana Fertig of the Good Food Institute argued that plant-based, fermentation-derived, and cultivated proteins can reduce greenhouse gas emissions, land use, and water use while helping California meet its climate and conservation goals. Zane Swanson of CSIS added that alternative proteins could reduce risks tied to zoonotic disease, antimicrobial resistance, supply-chain disruption, and broader national security concerns. In questions, members discussed the role of pharmaceuticals in animal agriculture and how alternative proteins might complement, rather than replace, traditional farming by creating new markets for California crops and helping farmers diversify. The second panel featured industry leaders Ethan Brown of Beyond Meat, Myra Passick of Upside Foods, and Arye Elfenbein of Wildtype. Brown highlighted plant-based meat’s health and climate benefits, criticized misinformation campaigns against the sector, and urged better labeling, reduced subsidies for factory farming, and more plant-based food in public institutions. Passick described cultivated meat as a scalable food-production technology, said Upside Foods has already produced millions of pounds annually at its Emeryville facility, and asked for grants, low-interest loans, and possible participation in cap-and-trade or similar revenue programs. Elfenbein described cultivated seafood as a way to address overfishing, contamination, traceability problems, and the heavy import dependence of the U.S. seafood supply, while also noting conservation benefits and the need for California to remain a hub for the industry. The final panel centered on research and workforce development. UCLA’s Amy Rowat described state-funded work on technical bottlenecks such as growing fat cells and creating edible scaffolds, along with a Future Food Fellows program that trains students across science, engineering, law, and policy. UC Santa Cruz economist Galina Hale argued that alternative proteins are necessary to meet future protein demand while reducing food-system emissions, and said California must support the sector through grants, loans, procurement, and research centers to avoid losing leadership to other states and countries. The hearing ended with the chair thanking the witnesses, noting that all materials would be posted online, and saying the committee would continue building policy and budget proposals to support the sector.

Transcript Highlights:

• When combined with psychological support, psychedelic compounds... ...strides.
• You know, we're not trying to be a... ...pharmaceutical that brings a drug to market.
• It's compounding. Post-traumatic stress. It's acute. It's chronic. It's compounding.
• And that constant repeated exposure compounds.
• And that compounding, consistent, repeated exposure is killing our people.

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies held an informational hearing focused on psychedelic-assisted treatments for PTSD, depression, addiction, and related conditions, especially for veterans, first responders, and firefighters. The chair framed the issue as a response to long-standing barriers created by Schedule I restrictions and stigma, emphasizing that the committee was looking at supervised clinical use rather than take-home drugs. Members discussed the growing number of state psychedelic policy proposals, the federal breakthrough therapy pathway, and the idea of Arizona preparing for FDA approval and possibly sending correspondence to federal officials in support of expanded access and Right to Try implementation. Witnesses included retired Army Special Forces Master Sgt. Alan Mullen, who described participating in an ibogaine study for PTSD/TBI and said the treatment, combined with preparation and integration support, helped him confront trauma and showed promise under strict medical monitoring. Dr. Sue Sisley of Scottsdale Research Institute testified that her team is conducting FDA-controlled psychedelic trials, including psilocybin research funded by Arizona, and argued that these therapies can produce major symptom relief with limited doses when delivered in controlled settings. She also urged the legislature to help remove barriers to research and access, including support for Right to Try and possible federal action to allow controlled-substance access. Dan Freiberg of the Professional Fire Fighters of Arizona said firefighters face chronic mental health exposure and often lack effective options beyond traditional therapy or, in some cases, ketamine, and he supported any safe, effective treatment that could help members return to work and reduce suicide risk. Dr. Chung Trin, a mental health physician and trial investigator, explained the FDA breakthrough designation process, said several psychedelic treatments are in late-stage review, and stressed the need for Arizona to build clinical infrastructure so patients can access approved therapies quickly and safely once federal approval occurs. Committee members asked about safety, addiction potential, suicide risk, costs, patents, and whether natural versus synthetic versions of compounds like psilocybin would be available; the hearing ended with general support for continued research, possible legislative correspondence to federal officials, and no formal vote or bill action taken.

Transcript Highlights:

• Certain compounds now classified with interventional psychiatry date back to the 1950s and the '60s.
• When combined with psychological support, psychedelic compounds... ...strides.
• You know, we're not trying to be a pharmaceutical that brings a drug to market.
• It's compounding.
• And that compounding, consistent, repeated exposure is killing our people.

Keywords: 1182, all

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies met to discuss psychedelic-assisted treatments for serious mental health conditions, with a focus on psilocybin, ibogaine, MDMA, and related compounds. The chair framed the issue as a clinical and access problem for veterans, first responders, and others with PTSD, depression, TBI, addiction, and suicidal ideation, emphasizing that these therapies are intended for supervised medical settings rather than take-home use. Members reviewed research claims and policy trends, including FDA breakthrough therapy designations, state-level psychedelic legislation, and the role of Arizona’s right-to-try law in expanding access once federal approval is in place. Testimony came from Alan Mullen, a retired Army Special Forces veteran, who described his PTSD/TBI history and said ibogaine treatment helped him confront trauma and showed promise in reducing symptoms under strict medical monitoring. Dr. Sue Cisley of Scottsdale Research Institute described ongoing FDA-controlled trials in Arizona, said current medications often fail high-need patients, and urged removal of research barriers and preparation for right-to-try and expanded access. Dan Freiberg of the Professional Firefighters of Arizona said firefighters face chronic exposure to trauma, often rely on alcohol or other coping mechanisms, and need effective alternatives beyond traditional therapy. Dr. Chung Trin discussed late-stage psychedelic trials, the FDA breakthrough pathway, safety oversight, and the need for state readiness when approvals occur. Committee members asked about how the treatments work, whether they require psychotherapy support, safety concerns including suicidality and black-market abuse, patenting and synthetic versus natural versions, and costs compared with ketamine and other treatments. Witnesses said the therapies are administered with extensive screening, monitoring, and integration support, and argued that addiction potential appears low under medical supervision. The discussion ended with interest in sending correspondence to federal officials to support right-to-try cooperation and in continuing the research and policy work; no formal vote or action was taken in the portion provided.

Transcript Highlights:

• Sometimes the pendulum goes way too far on one side, and these vision benefit managers, pharmaceutical
• The general spoke that they're not counting pharmaceutical or drug overdoses as suicide.
• Nick Waltz, Louisiana Compound Pharmacy Coalition.
• Rachel Grosafco, Louisiana Compound Pharmacy Coalition.
• Louisiana Compound Pharmacy Coalition.

Bills: SCR37, SB145, SB237

Keywords: informed consent, healthcare, medical procedures, patient rights, surgeon general, regulatory review, adult residential care, generators, emergency power, health safety, Louisiana Department of Health, compliance, regulations, child welfare, Department of Children and Family Services, mandatory reporting, abuse prevention, investigative teams, child ombudsman, forensic interviews

Transcript Highlights:

• Safety overall, safety issues of pharmaceutical products, I don't dispute that.
• </c><02:03:12.800><c> I</c> issues of of pharmaceutical products.
• We are by no means trying to do away with compounding pharmacies.
• We want to honor the work that compounding pharmacies are doing.
• </c> want to honor the work that compounding want to honor the work that compounding pharmacies<02:08

Keywords: 981, all

Transcript Highlights:

• And I thought we were here to lower the cost of pharmaceutical drugs.
• This is a direct increase in the cost of pharmaceutical drugs.
• And so I would... ...direct increase in the cost of pharmaceutical drugs.
• And it's the people that we are negotiating with, largely the large pharmaceutical companies and the
• There was a huge problem with the increasing price of pharmaceutical drugs, and PBMs were a solution

Summary: The committee first took testimony on House Bill 1681, which would require health carriers and pharmacy benefit managers to count amounts paid by or on behalf of an enrollee for certain medications toward out-of-pocket maximums when no generic substitute is available. The sponsor described the bill as helping patients with serious illnesses afford needed drugs. The committee then adopted a substitute that rolled HB 1681 together with House Bills 1941 and 2279, including an ERISA-related labor exemption, and passed the combined committee substitute by a vote of 15-2. The committee next heard House Bill 2365, which was also combined with related bills through a substitute that changed terminology to “delivery systems.” That substitute was adopted by voice vote, and the House Committee substitute for House Bills 2365, 2490, and 2249 was then approved unanimously, 18-0. After that, the committee heard House Bill 2149, the dementia care coordinator bill. The sponsor and supporters from the Alzheimer’s Association and family caregivers argued the state needs a central point person to coordinate resources, improve early detection, support caregivers, and connect rural residents to services. Members raised concerns about the fiscal note, whether the work duplicates existing Area Agencies on Aging and Alzheimer’s Association services, and whether two FTEs would be effective statewide. No vote was taken on HB 2149 during the portion provided. The committee also heard House Bill 2309, which would prohibit Missouri insurance coverage for organ transplants or related services involving organs taken from prisoners of conscience in China. The sponsor and supporters framed the bill as a human-rights measure aimed at condemning organ harvesting and abuse of Falun Gong practitioners and other prisoners of conscience. Members asked whether there was documentation of such transplants in Missouri and whether federal oversight exists; the sponsor said there is no reporting mechanism and no known opposition. No action was taken on the bill in the excerpt. Finally, the committee began testimony on House Bills 1975 and 1850, pharmacy benefit manager reform bills. The sponsors said the measures are intended to protect local pharmacies, improve transparency, limit harmful audit practices, and create a critical access pharmacy program. Supporters, including a pharmacy business group, argued PBM practices drive up drug costs and close pharmacies. Opponents, including a carpenters’ health plan representative, warned the bills could increase costs for self-funded plans, limit network and mail-order arrangements, and shift more administrative burden onto plan sponsors. The hearing continued with questions and testimony, but no final vote is shown in the provided transcript.

Transcript Highlights:

• narcotic drugs, including synthetic 7-hydroxymitragynine, commonly referred to as 7-OH, and any compound

Bills: HB2028, HB2047, HB2136, HB2244, HB2364, HB2406, HB2415, HB2557, HB2573, HB2589, HB2720, HB2749, HB2825, HB2861, HB2862, HB2870, HB2970, HB4070, HB4117, HCR2004, HCR2051

Keywords: community restitution, homelessness, indigence, court assessments, monetary obligations, forcible entry, detainer, writ of restitution, criminal trespass, judgment enforcement, civil terrorism, disorderly conduct, vandalism, political activism, public order, subversion, government security, evictions, judgment satisfaction, tenant rights

Bills: HB2076, HB2135, HB2175, HB2186, HB2223, HB2345, HB2364, HB2417, HB2440, HB2666, HB2763, HCR2043

Keywords: school safety, employee training, firearm certification, crisis response, school policies, reimbursement fund, local law enforcement, HB2135, Arizona, civil liability, private right of action, DEI, diversity equity and inclusion, critical race theory, anti-racism, race stereotyping, sex stereotyping, race scapegoating, sex scapegoating, gender identity

Transcript Highlights:

• Sometimes the pendulum goes way too far on one side, and these vision benefit managers, pharmaceutical
• The general spoke that they're not counting pharmaceutical or drug overdoses as suicide.
• There's the reason why we would want to do this now is so these compound pharmacies can source the proper
• Nick Waltz, Louisiana Compound Pharmacy Coalition.
• Louisiana Compound Pharmacy Coalition.

Summary: The House Committee on Health and Welfare met on April 28 with a quorum and took up several Senate bills, beginning with SB 113 on the local health care provider participation program in Calcasieu Parish. The committee adopted a technical amendment and heard that the bill would shift the local sponsor from the parish to the city if needed by a June 1 deadline. After brief discussion and no opposition, SB 113 was reported favorably with amendments. The committee then approved SB 23, which exempts certain assisted living facilities licensed by LDH from the definition of food service establishment, and SB 150, which would allow LDH to scan and electronically store vital records supporting documents and return originals to citizens. SB 221 also advanced after testimony that it would allow EMS providers to be reimbursed by Medicaid for emergency responses where treatment is provided on scene but the patient is not transported. Members discussed that the bill could reduce unnecessary ER use and likely would require some rulemaking, but it was reported favorably. A major portion of the meeting focused on SB 404, a broad vision benefit plan reform bill. Supporters, including optometrists, said the measure would improve transparency, patient choice, and access to eye care by limiting restrictive plan practices; opponents from the vision care plan industry argued it was an unprecedented, provider-driven overhaul that could raise costs and reduce flexibility. After extensive testimony and an agreed amendment clarifying network participation, the committee reported SB 404 favorably with amendments. The committee also reported SB 32 favorably with amendments after emotional testimony from parents and advocates about perinatal bereavement care, cooling devices, and training for hospitals to give grieving families more time and dignity after infant loss. Finally, the committee heard SB 43, which would create a psychedelic-assisted therapy initiative within LDH for clinical research and treatment involving ibogaine and psilocybin, with testimony from veterans, researchers, and advocates describing potential benefits for PTSD, substance use, and traumatic brain injury. The bill was reported favorably with amendments and set to pass a courtesy sheet. The committee then began SB 253, a bill regulating peptides and compounding pharmacies, adopted technical amendments clarifying provider liability, and continued discussion as the transcript ended.

Transcript Highlights:

• One is there is a potential that biosolids have trace heavy metals, various pharmaceuticals, PFOS, the
• Pharmaceuticals are going to be in this waste stream.
• Some of those pharmaceuticals are destroyed in the process, but there are other pharmaceuticals that
• Some of those pharmaceuticals are destroyed in the process. but there are other pharmaceuticals that
• The PFAS compounds, uh, we don't know.

Summary: The meeting focused on the use of biosolids on farm and ranch land, with testimony from Oklahoma State University experts, a conservation official, and an engineering representative about the benefits, risks, and regulatory implications. Dr. Lusk described OSU’s long history of soil fertility research and said biosolids can provide nutrients and organic matter, but also may carry contaminants such as PFAS, heavy metals, pharmaceuticals, microplastics, and pathogens. He emphasized that many questions remain unanswered, especially about contaminant uptake into soil, crops, livestock, and humans, and said existing EPA and Oklahoma DEQ regulations address some treatment and application standards but may not fully cover PFAS. Dr. Arnell expanded on nutrient management, explaining that biosolids can function similarly to manure as a fertilizer source, especially for nitrogen and phosphorus, but should be tested, incorporated into soil, and applied under permit conditions to reduce runoff and other losses. He said PFAS testing methods are not yet standardized and that more research is needed to determine sampling protocols, movement in soil, and long-term effects. Committee members asked whether farmers and ranchers should be notified of risks, whether PFAS is currently tested, how many counties use biosolids, and what research would be needed for a dissertation-level study. The witnesses generally agreed that landowners should be informed of known risks and uncertainties, but said the science is still developing. Dr. Arnell said a unified testing method is needed before reliable PFAS monitoring can be done, and suggested that a multi-year study would be required to understand soil movement, crop uptake, and livestock impacts. Greg Scott of the Oklahoma Conservation Commission framed the issue as a waste-management problem, noting that human waste streams contain contaminants and that soil type affects how pollutants move; he said sandy soils pose greater movement risks than clay soils and that current best practice is incorporation, careful timing, and avoiding steep or sensitive sites. He also said PFAS are widespread and not naturally occurring in the way some other compounds are, and that liability and cleanup costs are major concerns. Mary Elizabeth Mock of Garver Engineering focused on the practical and financial consequences of a possible moratorium on land application, saying most of Oklahoma’s biosolids are currently land applied and would otherwise have to go to landfills. She warned that many landfills are nearing capacity, tipping fees could rise sharply, and cities such as Tulsa and Norman could face large increases in disposal costs, which would ultimately be borne by ratepayers and taxpayers. She also said septic system maintenance costs could rise if land application options shrink, potentially leading to deferred maintenance and system failures. Mock urged a tiered, data-driven approach to PFAS regulation and said advanced treatment technologies may help in the future, but they are still emerging and expensive. No votes were taken; the session consisted of presentations and member questions.

Transcript Highlights:

• </c><04:12:00.640><c> hazardous</c> to exclude pharmaceutical hazardous to exclude pharmaceutical hazardous
• These are the DEA pharmaceutical takeback days that happen twice a year.
• drugs in there, no pharmaceutical drugs in there, no questions<04:13:42.560><c> asked.
• There's pharmaceuticals, there's heavy metals, there's other contaminants.
• </c><05:42:05.600><c> listed</c> are more than 6 million compounds listed are more than 6 million compounds

Keywords: 1189, house, all

Transcript Highlights:

• But it doesn't prevent compounding; compounding can still occur if these checks are met. Mr.
• First, the FDA does not approve or disapprove compounded medications or active pharmaceutical ingredients
• Borg, how many GLP-1 doses are you compounding? How many GLP-1 are we compounding?
• We do compound some GLP-1.
• used in compounding.

Summary: The committee began with a presentation from Berthold Barak Karlich of Benor Capital on investment and innovation from a European perspective. He argued that legacy in trade and innovation is about enabling future generations, not isolation, and highlighted Austria and Europe’s strengths in education, applied research, hidden-champion SMEs, and deep-tech. He also warned against economic nationalism and emphasized that entrepreneurship and cross-border trade create shared interests, peace, and long-term collaboration. In response to questions, he said Arizona had impressed him as a strong, international deep-tech hub, and he expressed interest in learning more about opportunities there. The committee then considered HB 2746, which creates a study committee on trade offices under the Arizona Commerce Authority to review existing trade offices, gather stakeholder input, and report recommendations by December 31, 2028. Members discussed oversight of Arizona’s trade offices in countries including Mexico, Korea, Taiwan, Japan, Romania, and Germany, and the sponsor said the bill would help evaluate effectiveness while identifying new opportunities. The bill received a due pass recommendation on a 7-0 vote. HB 2750, which establishes the Arizona-Sonora Trade Commission with legislative appointees, also received a due pass recommendation after members discussed its role as a complement to executive-branch efforts; it passed 5-1 with one present. The committee next heard HB 4036, a bill restricting the sale and distribution of compounded GLP-1 weight-loss drugs made with certain bulk drug substances and authorizing inspections by the State Board of Pharmacy. Supporters, including Novo Nordisk and the Partnership for Safe Medicines, argued the bill would address unsafe imported ingredients, impurities, misleading advertising, and a surge in mass compounding that they said exceeds the intent of compounding law. Opponents from the Arizona Pharmacy Association, compounding pharmacists, and a physician argued the bill would burden lawful compounders, raise costs, reduce access, and could harm patients who rely on compounded medications. After extensive debate, the committee failed to pass HB 4036 on a 5-5 vote. Finally, the committee took up HB 2765, as amended by a strike-everything amendment creating a vapor product manufacturer licensing framework, fees, penalties, and Department of Revenue oversight. The sponsor said the measure was intended to address illegal smuggling of vape products and protect children, while opponents argued it would burden lawful businesses and that the real problem was illicit actors outside the regulated market. The transcript ends during the discussion of this bill, before a final vote is recorded.